Email updates

Keep up to date with the latest news and content from BMC Women's Health and BioMed Central.

Open Access Open Badges Research article

Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data

Jayne E Edwards, R Andrew Moore* and Henry J McQuay

BMC Women's Health 2004, 4:5  doi:10.1186/1472-6874-4-5

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Patient characteristics

William Stones   (2004-08-19 19:44)  University of Southampton email

This paper prompted me to follow up the question of whether the patients in the studies reviewed were allowed to take the combined oral contraceptive pill. This is not mentioned as a specific exclusion criterion in the published papers. Dr Sahin (reference 13) was kind enough to confirm that pill users were indeed excluded. A response is not forthcoming so far from the corresponding author for reference 9.

Thus it seems to be a completely open question as to whether rofecoxib is effective for women using the combined oral contraceptive pill. This is rather extraordinary given that so many do use the pill in order to reduce dysmenorrhoea.

Two other points came up during my search of the Vioxx licensing documentation on the FDA website. Firstly, it is reassuring to note that rofecoxib had no effect on metabolism of the oral contraceptive pill- in contrast to valdecoxib which does seem to have some effect, albeit of uncertain clinical signficance. This is probably not so important in real life as pill users would typically be in their pill-free week while using analgesia for some days of the withdrawal bleed.

Secondly and more importantly, none of the studies have included participants under the age of 18. Thus we are at a loss as to how to advise younger women with dysmenorrhoea - who must represent at least a third of the population at risk of primary dysmenorrhoea- regarding rofecoxib.

One might wish that investigators would focus more closely on these important sub-groups of women with dysmenorrhoea, and not just do the 'easy' trials!

Competing interests

None to declare.


Post a comment